scPharmaceuticals Inc

NASDAQ:SCPH  
6.03
+0.19 (+3.25%)
Regulatory, Other Pre-Announcement

Scpharmaceuticals Inc Says Furoscix New Drug Application Resubmission Anticipated In Q3 2021

Published: 03/23/2021 11:40 GMT
scPharmaceuticals Inc (SCPH) - .
Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update.
Furoscix® New Drug Application Resubmission Anticipated in Q3 2021.
Freedom Clinical Study on Track for Topline Results in Q3 2021.
Qtrly Loss per Share $0.28.
Q4 Earnings per Share View $-0.36 -- Refinitiv Ibes Data (analyst estimates).
Forecasts Its 2021 Net Loss to Be $32 to $36 Million.